Cargando…
Liposomal Vincristine as a Bridge Therapy Prior to CAR-T Therapy in Relapsed and Refractory Diffuse Large B-Cell Lymphoma?
We report a case of a 76-year-old male with a history of relapsed and refractory diffuse large B-cell lymphoma (DLBCL).Our patient was initially treated with front line chemotherapy along with central nervous system (CNS) prophylaxis with complete response. He subsequently relapsed, was sensitive to...
Autores principales: | Chadha, Juskaran, Hussein, Shafinaz, Zhan, Yougen, Shulman, Jonah, Brody, Joshua, Ratner, Lynn, Steinberg, Amir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660481/ https://www.ncbi.nlm.nih.gov/pubmed/31372204 |
Ejemplares similares
-
Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
por: Ladbury, Colton, et al.
Publicado: (2023) -
Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine
por: Davis, Tyler, et al.
Publicado: (2013) -
Marqibo(®) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
por: Silverman, Jeffrey A., et al.
Publicado: (2012) -
Correction to “Folic acid-conjugated liposomal vincristine for multidrug resistant cancer therapy”
por: Wang, Chenyu, et al.
Publicado: (2022) -
Penile cancer: Updates in systemic therapy
por: Joshi, Vidhu B., et al.
Publicado: (2022)